Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RYBELSUS 1,5 MG COMPRIMIDOS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/RYBELSUS 1,5 MG COMPRIMIDOS

Approved

STANDARD

RYBELSUS 1,5 MG COMPRIMIDOS

Novo Nordisk A/S🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Apr 10, 2025
Approval ID: a0aac91fba1e95e2
Company: Novo Nordisk A/S
Type: Standard

Approval Details

Approval Id: a0aac91fba1e95e2
Drug Cima Aemps Name: RYBELSUS 1,5 MG COMPRIMIDOS
Register Number: 1201430017
Holder Company Name: Novo Nordisk A/S
Marketing Company Name: Novo Nordisk Pharma S.A.
Holder Company Detail Path: /organization/05f4a35c23475249/novo-nordisk-a-s
Authorization Date: 2025-04-10
Dosage Form: COMPRIMIDO
Dose: 1,5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Novo Nordisk A/S
Company Detail Path: /organization/05f4a35c23475249/novo-nordisk-a-s

Company Information

Pharmaceutical Company Name: Novo Nordisk A/S
Country Name: Denmark
City Name: bagsværd,hovedstaden,country_dk
Address: Novo Alle 1
Website: http://www.novonordisk.com

Active Ingredients

SEMAGLUTIDA

1,50 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Apr 10, 2025

Approval ID

a0aac91fba1e95e2

Type

Standard

Back to CIMA-AEMPS Approvals